Global Anti-cancer Insurance Market

Anti-cancer Insurance Comprehensive Study by Type (Benefit-based Anti-cancer Insurance, Reimbursable Anti-cancer Medical Insurance), Application (Lung Cancer, Liver Cancer, Others), End Use (Adult, Children) Players and Region - Global Market Outlook to 2028

Anti-cancer Insurance Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Anti-cancer Insurance
Cancer is a broad term for a variety of disorders characterised by the uncontrollable division of aberrant cells with the ability to infiltrate and destroy normal human tissue. Cancer has a high proclivity for spreading throughout the body. Cancer is the second largest cause for deaths in world. Globally, the cancer treatments are also very high, due to wide range of medications, therapies and expensive healthcare equipment required in the treatment. The death rates are also decreeing, due to presence of advanced medical facilities. With Increasing Penetration of Insurance market, people are opting for cancer specific insurance policies. Although, rising competition is creating certain friction. Similarly, the emergence of tech based alternatives to traditional insurance companies such as that from Ant Group are rising in popularity. Geographically, Asia Pacific is emerging as a major market outside North America and Europe in terms of high growth prospectus.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Anti-cancer Insurance market is a fragmented market due to the presence of various players. Companies are focusing on developing innovative products and solution to improve quality, enhances and promotes performance. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allianz SE (Germany), American International Group Inc. (United States), UnitedHealth Group Inc. (United States), MetLife, Inc. (United States), Ant Group (China), Prudential Plc (United Kingdom), Liberty Mutual Group (United States), Assicurazioni Generali S.p.A. (Italy), BNP Paribas Group (France), Axa S.A. (France) and China Life Insurance Company Ltd. (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Aviva plc (United Kingdom), Zurich Insurance Group Ltd. (Switzerland) and Aegon (India).

Segmentation Overview
AMA Research has segmented the market of Global Anti-cancer Insurance market by Type (Benefit-based Anti-cancer Insurance and Reimbursable Anti-cancer Medical Insurance), Application (Lung Cancer, Liver Cancer and Others) and Region.



On the basis of geography, the market of Anti-cancer Insurance has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Adult will boost the Anti-cancer Insurance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Benefit based Anti-cancer Insurance Accounts for Larger Market Share

Market Growth Drivers:
Rising Incidents of Cancer, High Cost of Cancer Treatment and Increasing Penetration of Insurance Market

Challenges:
Rising Competition due to Presence of Large Number of Players in Market

Restraints:
Less Awareness about Insurance in Developing Countries

Opportunities:
Asia Pacific Region Presents Huge Opportunity to Expand especially after Markets like India are Opening up for Foreign Investment in Insurance Sector

Market Leaders and their expansionary development strategies
In 2020, America’s largest mutual insurer company, New York Life Insurance Co. announced completion of acquisition of Cigna Corp.’s arm dealing with life, accident, and disability insurance business. The acquisition deal was valued at USD 6.3 billion, all in cash. The acquisition will significantly bolster New York Life’s market standings in the North American Market.
In 2021, Alliance Insurance, an India based Insurance brokers company announced a partnership with Clovia, which is a women’s personal care brand to launch a tailor made insurance policy to counter breast cancer known as “women’s cancer shield”. The deal involves clovia to be medium to reach out to consumers, whereas the Alliance would facilitate as the insurance partner aiding in breast cancer insurance policy.


Key Target Audience
Anti-cancer Insurance Providers, New Entrants/Investors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Benefit-based Anti-cancer Insurance
  • Reimbursable Anti-cancer Medical Insurance
By Application
  • Lung Cancer
  • Liver Cancer
  • Others
By End Use
  • Adult
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidents of Cancer
      • 3.2.2. High Cost of Cancer Treatment
      • 3.2.3. Increasing Penetration of Insurance Market
    • 3.3. Market Challenges
      • 3.3.1. Rising Competition due to Presence of Large Number of Players in Market
    • 3.4. Market Trends
      • 3.4.1. Benefit based Anti-cancer Insurance Accounts for Larger Market Share
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-cancer Insurance, by Type, Application, End Use and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-cancer Insurance (Value)
      • 5.2.1. Global Anti-cancer Insurance by: Type (Value)
        • 5.2.1.1. Benefit-based Anti-cancer Insurance
        • 5.2.1.2. Reimbursable Anti-cancer Medical Insurance
      • 5.2.2. Global Anti-cancer Insurance by: Application (Value)
        • 5.2.2.1. Lung Cancer
        • 5.2.2.2. Liver Cancer
        • 5.2.2.3. Others
      • 5.2.3. Global Anti-cancer Insurance by: End Use (Value)
        • 5.2.3.1. Adult
        • 5.2.3.2. Children
      • 5.2.4. Global Anti-cancer Insurance Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Anti-cancer Insurance: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allianz SE (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. American International Group Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. UnitedHealth Group Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. MetLife, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ant Group (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Prudential Plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Liberty Mutual Group (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Assicurazioni Generali S.p.A. (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BNP Paribas Group (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Axa S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. China Life Insurance Company Ltd. (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Anti-cancer Insurance Sale, by Type, Application, End Use and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-cancer Insurance (Value)
      • 7.2.1. Global Anti-cancer Insurance by: Type (Value)
        • 7.2.1.1. Benefit-based Anti-cancer Insurance
        • 7.2.1.2. Reimbursable Anti-cancer Medical Insurance
      • 7.2.2. Global Anti-cancer Insurance by: Application (Value)
        • 7.2.2.1. Lung Cancer
        • 7.2.2.2. Liver Cancer
        • 7.2.2.3. Others
      • 7.2.3. Global Anti-cancer Insurance by: End Use (Value)
        • 7.2.3.1. Adult
        • 7.2.3.2. Children
      • 7.2.4. Global Anti-cancer Insurance Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-cancer Insurance: by Type(USD Million)
  • Table 2. Anti-cancer Insurance Benefit-based Anti-cancer Insurance , by Region USD Million (2017-2022)
  • Table 3. Anti-cancer Insurance Reimbursable Anti-cancer Medical Insurance , by Region USD Million (2017-2022)
  • Table 4. Anti-cancer Insurance: by Application(USD Million)
  • Table 5. Anti-cancer Insurance Lung Cancer , by Region USD Million (2017-2022)
  • Table 6. Anti-cancer Insurance Liver Cancer , by Region USD Million (2017-2022)
  • Table 7. Anti-cancer Insurance Others , by Region USD Million (2017-2022)
  • Table 8. Anti-cancer Insurance: by End Use(USD Million)
  • Table 9. Anti-cancer Insurance Adult , by Region USD Million (2017-2022)
  • Table 10. Anti-cancer Insurance Children , by Region USD Million (2017-2022)
  • Table 11. South America Anti-cancer Insurance, by Country USD Million (2017-2022)
  • Table 12. South America Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 13. South America Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 14. South America Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 15. Brazil Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 16. Brazil Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 17. Brazil Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 18. Argentina Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 19. Argentina Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 20. Argentina Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 21. Rest of South America Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 22. Rest of South America Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 23. Rest of South America Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 24. Asia Pacific Anti-cancer Insurance, by Country USD Million (2017-2022)
  • Table 25. Asia Pacific Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 26. Asia Pacific Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 27. Asia Pacific Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 28. China Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 29. China Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 30. China Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 31. Japan Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 32. Japan Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 33. Japan Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 34. India Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 35. India Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 36. India Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 37. South Korea Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 38. South Korea Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 39. South Korea Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 40. Taiwan Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 41. Taiwan Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 42. Taiwan Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 43. Australia Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 44. Australia Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 45. Australia Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 46. Rest of Asia-Pacific Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 49. Europe Anti-cancer Insurance, by Country USD Million (2017-2022)
  • Table 50. Europe Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 51. Europe Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 52. Europe Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 53. Germany Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 54. Germany Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 55. Germany Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 56. France Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 57. France Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 58. France Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 59. Italy Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 60. Italy Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 61. Italy Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 62. United Kingdom Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 63. United Kingdom Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 64. United Kingdom Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 65. Netherlands Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 66. Netherlands Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 67. Netherlands Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 68. Rest of Europe Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 69. Rest of Europe Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 70. Rest of Europe Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 71. MEA Anti-cancer Insurance, by Country USD Million (2017-2022)
  • Table 72. MEA Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 73. MEA Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 74. MEA Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 75. Middle East Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 76. Middle East Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 77. Middle East Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 78. Africa Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 79. Africa Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 80. Africa Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 81. North America Anti-cancer Insurance, by Country USD Million (2017-2022)
  • Table 82. North America Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 83. North America Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 84. North America Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 85. United States Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 86. United States Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 87. United States Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 88. Canada Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 89. Canada Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 90. Canada Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 91. Mexico Anti-cancer Insurance, by Type USD Million (2017-2022)
  • Table 92. Mexico Anti-cancer Insurance, by Application USD Million (2017-2022)
  • Table 93. Mexico Anti-cancer Insurance, by End Use USD Million (2017-2022)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Anti-cancer Insurance: by Type(USD Million)
  • Table 106. Anti-cancer Insurance Benefit-based Anti-cancer Insurance , by Region USD Million (2023-2028)
  • Table 107. Anti-cancer Insurance Reimbursable Anti-cancer Medical Insurance , by Region USD Million (2023-2028)
  • Table 108. Anti-cancer Insurance: by Application(USD Million)
  • Table 109. Anti-cancer Insurance Lung Cancer , by Region USD Million (2023-2028)
  • Table 110. Anti-cancer Insurance Liver Cancer , by Region USD Million (2023-2028)
  • Table 111. Anti-cancer Insurance Others , by Region USD Million (2023-2028)
  • Table 112. Anti-cancer Insurance: by End Use(USD Million)
  • Table 113. Anti-cancer Insurance Adult , by Region USD Million (2023-2028)
  • Table 114. Anti-cancer Insurance Children , by Region USD Million (2023-2028)
  • Table 115. South America Anti-cancer Insurance, by Country USD Million (2023-2028)
  • Table 116. South America Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 117. South America Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 118. South America Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 119. Brazil Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 120. Brazil Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 121. Brazil Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 122. Argentina Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 123. Argentina Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 124. Argentina Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 125. Rest of South America Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 126. Rest of South America Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 127. Rest of South America Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 128. Asia Pacific Anti-cancer Insurance, by Country USD Million (2023-2028)
  • Table 129. Asia Pacific Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 130. Asia Pacific Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 131. Asia Pacific Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 132. China Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 133. China Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 134. China Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 135. Japan Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 136. Japan Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 137. Japan Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 138. India Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 139. India Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 140. India Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 141. South Korea Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 142. South Korea Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 143. South Korea Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 144. Taiwan Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 145. Taiwan Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 146. Taiwan Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 147. Australia Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 148. Australia Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 149. Australia Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 150. Rest of Asia-Pacific Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 151. Rest of Asia-Pacific Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 152. Rest of Asia-Pacific Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 153. Europe Anti-cancer Insurance, by Country USD Million (2023-2028)
  • Table 154. Europe Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 155. Europe Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 156. Europe Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 157. Germany Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 158. Germany Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 159. Germany Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 160. France Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 161. France Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 162. France Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 163. Italy Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 164. Italy Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 165. Italy Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 166. United Kingdom Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 167. United Kingdom Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 168. United Kingdom Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 169. Netherlands Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 170. Netherlands Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 171. Netherlands Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 172. Rest of Europe Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 173. Rest of Europe Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 174. Rest of Europe Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 175. MEA Anti-cancer Insurance, by Country USD Million (2023-2028)
  • Table 176. MEA Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 177. MEA Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 178. MEA Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 179. Middle East Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 180. Middle East Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 181. Middle East Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 182. Africa Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 183. Africa Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 184. Africa Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 185. North America Anti-cancer Insurance, by Country USD Million (2023-2028)
  • Table 186. North America Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 187. North America Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 188. North America Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 189. United States Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 190. United States Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 191. United States Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 192. Canada Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 193. Canada Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 194. Canada Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 195. Mexico Anti-cancer Insurance, by Type USD Million (2023-2028)
  • Table 196. Mexico Anti-cancer Insurance, by Application USD Million (2023-2028)
  • Table 197. Mexico Anti-cancer Insurance, by End Use USD Million (2023-2028)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-cancer Insurance: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-cancer Insurance: by Application USD Million (2017-2022)
  • Figure 6. Global Anti-cancer Insurance: by End Use USD Million (2017-2022)
  • Figure 7. South America Anti-cancer Insurance Share (%), by Country
  • Figure 8. Asia Pacific Anti-cancer Insurance Share (%), by Country
  • Figure 9. Europe Anti-cancer Insurance Share (%), by Country
  • Figure 10. MEA Anti-cancer Insurance Share (%), by Country
  • Figure 11. North America Anti-cancer Insurance Share (%), by Country
  • Figure 12. Global Anti-cancer Insurance share by Players 2022 (%)
  • Figure 13. Global Anti-cancer Insurance share by Players (Top 3) 2022(%)
  • Figure 14. Global Anti-cancer Insurance share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allianz SE (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Allianz SE (Germany) Revenue: by Geography 2022
  • Figure 18. American International Group Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. American International Group Inc. (United States) Revenue: by Geography 2022
  • Figure 20. UnitedHealth Group Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. UnitedHealth Group Inc. (United States) Revenue: by Geography 2022
  • Figure 22. MetLife, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. MetLife, Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Ant Group (China) Revenue, Net Income and Gross profit
  • Figure 25. Ant Group (China) Revenue: by Geography 2022
  • Figure 26. Prudential Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Prudential Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 28. Liberty Mutual Group (United States) Revenue, Net Income and Gross profit
  • Figure 29. Liberty Mutual Group (United States) Revenue: by Geography 2022
  • Figure 30. Assicurazioni Generali S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 31. Assicurazioni Generali S.p.A. (Italy) Revenue: by Geography 2022
  • Figure 32. BNP Paribas Group (France) Revenue, Net Income and Gross profit
  • Figure 33. BNP Paribas Group (France) Revenue: by Geography 2022
  • Figure 34. Axa S.A. (France) Revenue, Net Income and Gross profit
  • Figure 35. Axa S.A. (France) Revenue: by Geography 2022
  • Figure 36. China Life Insurance Company Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 37. China Life Insurance Company Ltd. (China) Revenue: by Geography 2022
  • Figure 38. Global Anti-cancer Insurance: by Type USD Million (2023-2028)
  • Figure 39. Global Anti-cancer Insurance: by Application USD Million (2023-2028)
  • Figure 40. Global Anti-cancer Insurance: by End Use USD Million (2023-2028)
  • Figure 41. South America Anti-cancer Insurance Share (%), by Country
  • Figure 42. Asia Pacific Anti-cancer Insurance Share (%), by Country
  • Figure 43. Europe Anti-cancer Insurance Share (%), by Country
  • Figure 44. MEA Anti-cancer Insurance Share (%), by Country
  • Figure 45. North America Anti-cancer Insurance Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allianz SE (Germany)
  • American International Group Inc. (United States)
  • UnitedHealth Group Inc. (United States)
  • MetLife, Inc. (United States)
  • Ant Group (China)
  • Prudential Plc (United Kingdom)
  • Liberty Mutual Group (United States)
  • Assicurazioni Generali S.p.A. (Italy)
  • BNP Paribas Group (France)
  • Axa S.A. (France)
  • China Life Insurance Company Ltd. (China)
Additional players considered in the study are as follows:
Aviva plc (United Kingdom) , Zurich Insurance Group Ltd. (Switzerland) , Aegon (India)
Select User Access Type

Key Highlights of Report


Apr 2023 220 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-cancer Insurance Market Quantitative research analysis
Global Anti-cancer Insurance Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allianz SE (Germany), American International Group Inc. (United States), UnitedHealth Group Inc. (United States), MetLife, Inc. (United States), Ant Group (China), Prudential Plc (United Kingdom), Liberty Mutual Group (United States), Assicurazioni Generali S.p.A. (Italy), BNP Paribas Group (France), Axa S.A. (France) and China Life Insurance Company Ltd. (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Benefit based Anti-cancer Insurance Accounts for Larger Market Share" is seen as one of major influencing trends for Anti-cancer Insurance Market during projected period 2022-2028.
The Anti-cancer Insurance market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Anti-cancer Insurance Market Report?

Have a Query? Click Here

Other Related Reports

Death Insurance Comprehensive Study by Type (1 Year, 5 Years, 10 Years, 15 Years, 20 Years, 30 Years), Application (Children, Adults, Senior Citizens) Players and Region - Global Market Outlook to 20...
$ 3500
Data Analytics In L&H Insurance Comprehensive Study by Application (Predictive Analysis, Demographic Profiling, Data Visualization, Others), Pricing (Subscription-based, One Time), Features (Future D...
$ 3650
Life and Non-Life Insurance Comprehensive Study by Type (Individual, Group), Application (Direct, Agency, Banks), Life Insurance (Whole Life Insurance, Term Life Insurance, Universal Life Insurance, ...
$ 3750
Long Term Care Insurance Comprehensive Study by Type (Partnership Long Term Care Insurance, Indemnity Long Term Care Insurance, Reimbursement Long Term Care Insurance), Age Group (Above 60 years, Bel...
$ 3450
Traffic Accident Insurance Comprehensive Study by Type (Individual Accident, Group Accident), Distribution Channel (Agents, Brokers, Bancassurance, Digital & Direct Channels, Others), Service (Ambula...
$ 3750
Baby Insurance Comprehensive Study by Type (Child ULIP, Child Endowment Plans, Regular Premium Child Plan, Single-Premium Child Plan, Others), Application (Agency, Digital & Direct Channels, Brokers,...
$ 3450